Why the study?
How should dental surgeons manage patients taking new generation antiplatelet and anticoagulant medications during invasive procedures?
How should dental surgeons manage patients taking new generation antiplatelet and anticoagulant medications during invasive procedures?
This review provides guidance for dental surgeons managing patients on newer antiplatelet and anticoagulant medications during invasive procedures.
Answers are grounded in this paper and cite their sources.
Provides interim guidance for dental management of novel antithrombotics; leaves open need for prospective validation.
The management of dental patients taking either antiplatelet medication, anticoagulant medication or both has been well established in the previous literature. Recently, new generations of drugs have emerged which are becoming increasingly common, including direct thrombin inhibitors, factor X inhibitors and a new class of oral thienopyridines. The implications of these drugs for the dental surgeon are not yet fully known. Awareness remains low and there is very little information available within the literature on safe use during surgery. This review paper aims to provide some guidance for dental practitioners performing invasive procedures. CPD/CLINICAL RELEVANCE: A new generation of anticoagulant and antiplatelet drugs have serious implications for patients undergoing surgery and their use is increasing.
No takes yet. Share an insight, caveat, or question.
S.C. Johnston (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: